aboratory monitoring and the anti-coagulant effect of Edoxaban after total knee arthroplasty
Not Applicable
- Conditions
- The patients who will be performed TKA/THA
- Registration Number
- JPRN-UMIN000017220
- Lead Sponsor
- Hokkaido University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
bleeding risks bleeding tendency bleeding history uncontrollable hypertension Operation history within 30 days uncontrollable DM low body weight less than 50 kg Renal failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of DVT
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Edoxaban's anti-coagulant activity in post-TKA/THA patients compared to warfarin?
How does Edoxaban's efficacy in preventing DVT after TKA/THA compare to enoxaparin and rivaroxaban in clinical trials?
Which biomarkers correlate with Edoxaban's pharmacodynamic effects in JPRN-UMIN000017220 TKA/THA patients?
What adverse events are associated with Edoxaban use in arthroplasty patients and how are they managed?
Are there pharmacokinetic interactions between Edoxaban and other DOACs in post-arthroplasty anticoagulation strategies?